Bexarotene: a promising anticancer agent Liyan QuXiuwen Tang Mini Review 24 September 2009 Pages: 201 - 205
Mechanism-based receptor-binding model to describe the pharmacokinetic and pharmacodynamic of an anti-α5β1 integrin monoclonal antibody (volociximab) in cancer patients Chee M. NgS. BaiA. W. Tolcher Original Article 26 May 2009 Pages: 207 - 217
Preclinical rationale for combined use of endocrine therapy and 5-fluorouracil but neither doxorubicin nor paclitaxel in the treatment of endocrine-responsive breast cancer Junichi KurebayashiMamoru NukatsukaMamoru Kiniwa Original Article 20 May 2009 Pages: 219 - 225
A phase I study of larotaxel (XRP9881) administered in combination with carboplatin in chemotherapy-naïve patients with stage IIIB or stage IV non-small cell lung cancer Francisco RobertKaren HarperSunil Gupta Original Article 29 May 2009 Pages: 227 - 234
Phase 1 first-in-human clinical study of S-trans, trans-farnesylthiosalicylic acid (salirasib) in patients with solid tumors Apostolia Maria TsimberidouMichelle A. RudekRazelle Kurzrock Original Article 31 May 2009 Pages: 235 - 241
Phase I clinical and pharmacokinetic study of the glucose-conjugated cytotoxic agent d-19575 (glufosfamide) in patients with solid tumors Toshio ShimizuIsamu OkamotoKazuhiko Nakagawa Original Article 29 May 2009 Pages: 243 - 250
Association of UGT2B7 and ABCB1 genotypes with morphine-induced adverse drug reactions in Japanese patients with cancer Ken-ichi FujitaYuichi AndoYasutsuna Sasaki Original Article 23 May 2009 Pages: 251 - 258
Promising overall survival of patients with recurrent/metastatic squamous cell carcinoma of head and neck receiving gemcitabine plus cisplatin treatment: report of a multi-center phase II study Muh-Hwa YangPeter Mu-Hsin ChangPo-Min Chen Original Article 24 May 2009 Pages: 259 - 265
Celecoxib prevents tumor growth in an animal model by a COX-2 independent mechanism Amanda Leite Bastos-PereiraDaiana LugariniAlexandra Acco Original Article 09 June 2009 Pages: 267 - 276
Quercetin greatly improved therapeutic index of doxorubicin against 4T1 breast cancer by its opposing effects on HIF-1α in tumor and normal cells Gangjun DuHaihong LinLijuan Yu Original Article 26 May 2009 Pages: 277 - 287
Dual targeting of tumour cells and host endothelial cells by novel microtubule-targeting agents, pyrrolo-1,5-benzoxazepines Seema-Maria NathwaniStephen ButlerDaniela M. Zisterer Original Article 29 May 2009 Pages: 289 - 300
Phase I/II study of the lipiodolization using DDP-H (CDDP powder; IA-call®) in patients with unresectable hepatocellular carcinoma Yo-ichi YamashitaAkinobu TaketomiYoshihiko Maehara Original Article 03 June 2009 Pages: 301 - 307
Effect of antisense oligomer in controlling c-raf.1 overexpression during diethylnitrosamine-induced hepatocarcinogenesis in rat Tanushree DasFalguni PatraBiswajit Mukherjee Original Article 05 June 2009 Pages: 309 - 318
Capped-dose mitomycin C: a pooled safety analysis from three prospective clinical trials Nse NtukidemCarlos Arce-LaraTanios Bekaii-Saab Original Article 09 June 2009 Pages: 319 - 324
Quantitative structure–property relationships of camptothecins in humans Chao XuThomas M. BarchetDonald E. Mager Original Article 02 June 2009 Pages: 325 - 333
Tyrosine kinase inhibitors and multidrug resistance proteins: interactions and biological consequences Amalia AzzaritiLetizia PorcelliAngelo Paradiso Original Article 04 June 2009 Pages: 335 - 346
The effect of transcatheter arterial chemoembolization on phase II drug metabolism enzymes in patients with hepatocellular carcinoma Yan ZhangYanyan JiaAidong Wen Original Article 11 June 2009 Pages: 347 - 352
A phase I/II trial of GW572016 (lapatinib) in recurrent glioblastoma multiforme: clinical outcomes, pharmacokinetics and molecular correlation Brian ThiessenClinton StewartElizabeth Eisenhauer Original Article 05 June 2009 Pages: 353 - 361
A water soluble prodrug of a novel camptothecin analog is efficacious against breast cancer resistance protein-expressing tumor xenografts Mika EndoMasanori MiwaHisafumi Yamada-Okabe Original Article 04 June 2009 Pages: 363 - 371
A randomized comparative study of high-dose and low-dose hepatic arterial infusion chemotherapy for intractable, advanced hepatocellular carcinoma Hyun Young WooSi Hyun BaeKorean Liver Cancer Study Group Clinical Trial Report 18 September 2009 Pages: 373 - 382
A phase I trial of UCN-01 and prednisone in patients with refractory solid tumors and lymphomas Shivaani KummarMartin E. GutierrezJames H. Doroshow Clinical Trial Report 06 November 2009 Pages: 383 - 389
Phase II study of fixed dose rate gemcitabine as radiosensitizer for newly diagnosed glioblastoma multiforme Giulio MetroAlessandra FabiCarmine M. Carapella Clinical Trial Report 22 October 2009 Pages: 391 - 397
Bevacizumab induced reversible thrombocytopenia in a patient with recurrent high-grade glioma: a case report Ticiana LealH. Ian Robins Short Communication 16 September 2009 Pages: 399 - 401
The contribution of deleterious DPYD gene sequence variants to fluoropyrimidine toxicity in British cancer patients Aathavan LoganayagamMonica Arenas-HernandezAnthony M. Marinaki Short Communication 01 October 2009 Pages: 403 - 406